Asthma Insight and Management (AIM), the largest and most comprehensive survey of asthma in the United States conducted in more than a decade, reveals limited progress in reducing hospitalizations and emergency room visits due to asthma over the past ten years.
Today, Schering-Plough Corporation announced the recipients of the 2009 Will to Win Scholarship Program, which recognizes high school seniors with asthma who are pursuing higher education. Ten scholarships of $5,000 have been awarded to two high school seniors in each of the five scholarship categories: performing arts, visual arts, community service, athletics and science.
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study of Liver Disease's (AASLD) Liver Meeting 2008 in San Francisco.
Arpida today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid.
Tibotec BVBA announced today that it has begun enrolling patients in its phase III clinical trial evaluating telaprevir, an investigational hepatitis C virus protease inhibitor, in patients who failed prior therapy with peginterferon (Peg-IFN) plus ribavarin (RBV). The trial, known as REALIZE, will compare the efficacy, safety and tolerability of telaprevir combined with Peg-IFN plus RBV versus Peg-IFN and RBV alone, the current standard of care. Investigators at U.S. trial centers have begun screening patients for participation in the study, with global centers expected to begin screening in the coming weeks.
The International Serious Adverse Events Consortium (SAEC) announced today that two new leading academic centers will collaborate with this novel, international research Consortium, which is working to identify genetic markers that may help predict which individuals are at risk for a range of serious drug-related adverse events (SAEs). These new research collaborators include the University of Malaga [Malaga, Spain] and the University of Dundee [Dundee, Spain].
The International Serious Adverse Events Consortium (SAEC) announced today that four new members have joined this novel research Consortium, which is working to identify genetic markers that may help predict which individuals are at risk for a range of serious drug-related adverse events (SAEs). These new members include pharmaceutical companies Takeda, Novartis and Daiichi Sankyo and the world's largest medical research charity, The Wellcome Trust.
AstraZeneca has reached important milestones for the company's investigational cancer drugs vandetanib and cediranib. In March, the company announced the completion of patient enrollment in three of four pivotal Phase III studies for vandetanib for the second-line treatment of non-small cell lung cancer. AstraZeneca announced in February that a Phase II/III study of cediranib for the first-line treatment of patients with advanced colorectal cancer will progress directly into Phase III.
Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are two serious and debilitating diseases with no confirmed cause and limited treatment options. However, results of a new comprehensive literature study propose a simplified treatment process that could help alleviate symptoms for patients suffering from these diseases.
AstraZeneca announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of NSCLC. The two studies "“ ZODIAC (ZACTIMA in Combination with Docetaxel In non-small cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) "“ are the second and third of four ongoing studies to complete enrollment.
The results from a randomized, double -blind, placebo -controlled, Phase II study of ZD4054 "“ a specific endothelin A receptor antagonist "“ were delivered today at the 14th European Congress of Clinical Oncology. The data presented today for ZD4054, an investigational compound in development for the treatment of men with hormone resistant prostate cancer, showed no differences in progression free survival but did report encouraging overall survival data.
The majority of breast cancer survivors consider themselves stronger after having the disease, according to new survey results released today. However, the data also suggest women's knowledge about actions they can take to lessen the likelihood of recurrence is surprisingly low.
Results of the SALT-1 and SALT-2 Trials show tolvaptan improves serum sodium levels in patients with hyponatremia.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right